Living mapping and living systematic review of Covid-19 studies

Studies registered


Registered studies


Randomized Trials (excluding Traditional Chinese Medicine trials)
994 RCTs recruiting



Records screened


Randomized Controlled trials

Weekly update: September 14, 2020 to September 18, 2020

Over the past week we have screened 4185 records.

On September 2, we have updated the study protocol with respect to:

  • Type of study: Given the increase in the number of randomized controlled trials, we decided to stop extracting data from Non-Randomized Studies.
  • Change in outcome: We will not collect data on the outcome 'recovery' as the definition provided by authors was too heterogeneous and redundant with the outcome 'clinical improvement'.
  • We identified and now report seven new RCTs on our website:

  • Agarwal et al, evaluating Convalescent plasma versus standard of care
  • Avendano-Sola et al, Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial
  • Rosas et al, Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
  • Wang et al, Tocilizumab Ameliorates the Hypoxia in COVID-19 Moderate Patients with Bilateral Pulmonary Lesions: A Randomized, Controlled, Open-Label, Multicenter Trial
  • Rahmani et al, Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
  • Lopes et al, Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial
  • Entrenas Castillo et al, evaluating Vitamin D versus standard of care

    We present this week a new page presenting the mapping of vaccine trials and a page presenting the living systematic review of vaccine randomized controlled trials We identified seven trials assessing several potential vaccines for COVID19 and we present data on one trial:

  • Zhu et al, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

    We have also included and presently extracting four new RCTs comparisons.

  • Cheng et al, evaluating Recombinant human granulocyte colony-stimulating factor (rhG-CSF) versus standard of care
  • Chowdhury et al, evaluating Ivermectin + Doxycycline versus Hydroxychloroquine +Azithromycin ,
  • Delgado-Enciso et al, evaluating Nebulized and/or Intravenous Neutral Electrolyzed Saline,
  • Farahani et al, evaluating corticosteroids.
  • Gharebaghi et al, evaluating intravenous immunoglobulin gamma ,
  • Li et al, evaluating Bromhexine versus standard of care ,
  • Some RCTs were extracted and pending awaiting author’s reply due to missing outcome data.

    Follow us on Twitter

  • To receive updates on our project and research findings, please subscribe to our digest, we will share with you new RCT results and other interesting news.

    Our main activities

    We are performing a living mapping of ongoing research followed by a living network meta-analysis of study results as soon as they are available.

    For more information on our methods see our protocol here.

    This work received some funding from the Agence Nationale de la Recherche (ANR), the World Health Organization (WHO), Cochrane France, Center of Research in Epidemiology and StatisticS (CRESS), Centre d’Epidémiologie Clinique (GHU Cochin, Hôtel Dieu, Assistance Publique Hôpitaux de Paris (APHP) and Université de Paris) and the Federal Ministry of Health, Germany

    We encourage all investigators of Randomized Controlled Trials to contact us as soon as they have results available.